CN1372935A - 克拉霉素缓释胶囊 - Google Patents
克拉霉素缓释胶囊 Download PDFInfo
- Publication number
- CN1372935A CN1372935A CN 02103847 CN02103847A CN1372935A CN 1372935 A CN1372935 A CN 1372935A CN 02103847 CN02103847 CN 02103847 CN 02103847 A CN02103847 A CN 02103847A CN 1372935 A CN1372935 A CN 1372935A
- Authority
- CN
- China
- Prior art keywords
- described pharmaceutical
- pharmaceutical preparation
- medicine
- preparation
- sodium lauryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000006187 pill Substances 0.000 claims abstract description 5
- 239000011248 coating agent Substances 0.000 claims description 22
- 238000000576 coating method Methods 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 15
- 229960002626 clarithromycin Drugs 0.000 claims description 12
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000003361 porogen Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 238000007789 sealing Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 150000002596 lactones Chemical class 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- -1 hydroxypropyl Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 15
- 229960003276 erythromycin Drugs 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000005453 pelletization Methods 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
聚合物包衣量(%) | 释放度 | |||||||
1 | 2 | 3 | 4 | 6 | 8 | 10 | 12 | |
4.8 | 40.1 | 66.1 | 76.2 | 87.7 | 93.7 | 93.6 | 94.2 | 98.6 |
5.4 | 16.5 | 28.6 | 44.6 | 55.7 | 89.7 | 103.6 | 104.9 | 106.5 |
7.2 | 3.5 | 4.4 | 8.7 | 15.0 | 25.5 | 37.5 | 55.7 | 74.6 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021038473A CN1165313C (zh) | 2002-04-02 | 2002-04-02 | 克拉霉素缓释胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021038473A CN1165313C (zh) | 2002-04-02 | 2002-04-02 | 克拉霉素缓释胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1372935A true CN1372935A (zh) | 2002-10-09 |
CN1165313C CN1165313C (zh) | 2004-09-08 |
Family
ID=4739915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021038473A Expired - Lifetime CN1165313C (zh) | 2002-04-02 | 2002-04-02 | 克拉霉素缓释胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1165313C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322866C (zh) * | 2004-10-12 | 2007-06-27 | 广州贝氏药业有限公司 | 一种多单元缓释制剂 |
CN100448433C (zh) * | 2005-09-21 | 2009-01-07 | 广州贝氏药业有限公司 | 一种克拉霉素肠溶药物组合物 |
CN103405462A (zh) * | 2013-07-27 | 2013-11-27 | 丽珠集团丽珠制药厂 | 一种含有艾普拉唑组合物的复方胶囊及其制备方法 |
CN103432149A (zh) * | 2013-07-27 | 2013-12-11 | 丽珠集团丽珠制药厂 | 一种含有艾普拉唑钠组合物的复方胶囊及其制备方法 |
CN107625733A (zh) * | 2016-07-14 | 2018-01-26 | 北京科信必成医药科技发展有限公司 | 一种克拉霉素无水吞服颗粒剂及其制备方法 |
CN112471145A (zh) * | 2020-12-04 | 2021-03-12 | 王立强 | 一种超高分子固体缓释消毒抑菌剂及其制备方法 |
-
2002
- 2002-04-02 CN CNB021038473A patent/CN1165313C/zh not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322866C (zh) * | 2004-10-12 | 2007-06-27 | 广州贝氏药业有限公司 | 一种多单元缓释制剂 |
CN100448433C (zh) * | 2005-09-21 | 2009-01-07 | 广州贝氏药业有限公司 | 一种克拉霉素肠溶药物组合物 |
CN103405462A (zh) * | 2013-07-27 | 2013-11-27 | 丽珠集团丽珠制药厂 | 一种含有艾普拉唑组合物的复方胶囊及其制备方法 |
CN103432149A (zh) * | 2013-07-27 | 2013-12-11 | 丽珠集团丽珠制药厂 | 一种含有艾普拉唑钠组合物的复方胶囊及其制备方法 |
CN103432149B (zh) * | 2013-07-27 | 2016-01-27 | 丽珠集团丽珠制药厂 | 一种含有艾普拉唑钠组合物的复方胶囊及其制备方法 |
CN103405462B (zh) * | 2013-07-27 | 2016-07-06 | 丽珠集团丽珠制药厂 | 一种含有艾普拉唑组合物的复方胶囊及其制备方法 |
CN107625733A (zh) * | 2016-07-14 | 2018-01-26 | 北京科信必成医药科技发展有限公司 | 一种克拉霉素无水吞服颗粒剂及其制备方法 |
CN112471145A (zh) * | 2020-12-04 | 2021-03-12 | 王立强 | 一种超高分子固体缓释消毒抑菌剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1165313C (zh) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0391518B1 (en) | Sustained-release pharmaceutical preparation | |
FI97686B (fi) | Menetelmä helmien valmistamiseksi tarkoituksena tuottaa hallitusti vapauttavia tuotteita | |
CN1037933C (zh) | 在大肠内具有释放能力的包衣固体药物型的制备方法 | |
CA1288050C (en) | Nitrofurantoin dosage form | |
KR20190000931A (ko) | 리팍시민의 고형 분산물 | |
CN1056057C (zh) | 口服延缓释放的曲美他嗪药物组合物 | |
EP1318792A2 (en) | Sustained release composition containing clarithromycin | |
US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
CN1165313C (zh) | 克拉霉素缓释胶囊 | |
US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
CN100376250C (zh) | 一种克拉霉素速释微丸及其制备方法 | |
Sahasathian et al. | Sustained release of amoxicillin from chitosan tablets | |
CN101002747A (zh) | 头孢克洛的缓释制剂 | |
PL213804B1 (pl) | Uklad terapeutyczny do podawania amoksycyliny i kwasu klawulanowego, oraz kapsulka unoszaca sie na powierzchni cieczy | |
CN101002745A (zh) | 头孢地尼的缓释制剂 | |
DE112006001548T5 (de) | Ticlopidin-Zusammensetzungen mit modifizierter Freisetzung | |
CN101084904B (zh) | 头孢克肟缓释双层片 | |
CN1180779C (zh) | 罗红霉素缓释胶囊及制备方法 | |
EP2704698B1 (de) | Arzneiform zur gezielten freigabe von wirkstoffen | |
CN103655506A (zh) | 一种头孢克洛缓释片及其制备方法 | |
CN112263569B (zh) | 一种阿莫西林胶囊及其制备方法 | |
US20100178326A1 (en) | Aminophosphonate carriers for liposome-based drug release systems | |
CN102970980A (zh) | 控制释放的左乙拉西坦配方 | |
CN101015529A (zh) | 阿莫西林双氯西林的缓释制剂 | |
CN1569016A (zh) | 一种克拉霉素缓释胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU BOSAILUO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: GUANGZHOU GUANGZHOU BEISHI PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Huadu District, Guangzhou, Xinhua new town, East Road, No. 9 Patentee after: GUANGZHOU PASAILUO PHARMACEUTICAL CO., LTD. Address before: Guangzhou, Guangdong Province, Huadu District, Port Industrial Development Zone, East Sau Road, No. 9 Patentee before: Bei's Pharmaceutical Co., Ltd, Guangzhou |
|
CX01 | Expiry of patent term |
Granted publication date: 20040908 |
|
CX01 | Expiry of patent term |